Clinical collaboration ALZN001 lithium-based therapy and ALZN002 cell-based vaccine programs are at clinical-stage with ongoing Phase II initiatives and academic partnerships (e.g., Massachusetts General Hospital). This presents opportunities for research collaborations, contract research, and co-development discussions with translational scientists and network hospitals.

Imaging partnerships Recent focus on advanced imaging for AL001 using AI-powered and X-Nuclei MR techniques, with partnerships (QMENTA) and presentations at ISMRM events. This creates potential sales talks for imaging services, data analytics platforms, and tech licenses to CROs, hospitals, and imaging centers pursuing similar trials.

Targeted neuroscience market Company targets Alzheimer’s disease, bipolar disorder, MDD and PTSD, addressing substantial US patient populations. This suggests expansion potential with payer discussions, companion diagnostics, and marketed-access strategies to neurologists, psychiatrists, and integrated delivery networks.

Funding and scale With revenue in the low millions and approximately $30M in funding, Alzamend Neuro appears lean but biopsy-ready for partnerships that de-risk development (co-funding, milestone-based deals) and scale Clinical Operations through CROs and biotech-focused financial partners.

Global visibility Active participation in investor events and conferences (ISMRM, Military Health System, SOT) implies urgency to attract strategic investors and potential licensing partners. Use these touchpoints to position BD conversations around strategic alliances, licensing, and access to capital for expansion.